Clinical trial

S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

NCT02728596

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-10-07

PhaseNA

Study timeline

Study start (actual)2016-10-07Date precision: day

Registry last updated2022-10-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Febrile Neutropeniaunresolved

Stage 0 Breast Cancerunresolved

Stage 0 Colorectal Cancerunresolved

Stage 0 Non-Small Cell Lung Cancerunresolved

Stage I Colorectal Cancerunresolved

Stage IA Breast Cancerunresolved

Stage IA Non-Small Cell Lung Carcinomaunresolved

Stage IB Breast Cancerunresolved

Stage IB Non-Small Cell Lung Carcinomaunresolved

Stage IIA Breast Cancerunresolved

Stage IIA Colorectal Cancerunresolved

Stage IIA Non-Small Cell Lung Carcinomaunresolved

Stage IIB Breast Cancerunresolved

Stage IIB Colorectal Cancerunresolved

Stage IIB Non-Small Cell Lung Carcinomaunresolved

Stage IIC Colorectal Cancerunresolved

Stage IIIA Breast Cancerunresolved

Stage IIIA Colorectal Cancerunresolved

Stage IIIA Non-Small Cell Lung Cancerunresolved

Stage IIIB Breast Cancerunresolved

Stage IIIB Colorectal Cancerunresolved

Stage IIIB Non-Small Cell Lung Cancerunresolved

Stage IIIC Breast Cancerunresolved

Stage IIIC Colorectal Cancerunresolved

Stage IV Breast Cancerunresolved

Stage IV Non-Small Cell Lung Cancerunresolved

Stage IVA Colorectal Cancerunresolved

Stage IVB Colorectal Cancerunresolved

Interventions

Preventive InterventionOTHER

Quality-of-Life AssessmentOTHER

Questionnaire AdministrationOTHER

Sponsors & collaborators

SWOG Cancer Research Networklead sponsor

National Cancer Institute (NCI)collaborator

Patient-Centered Outcomes Research Institutecollaborator

Mapped research locations

GreenvilleSouth Carolina, United States4 SeattleWashington, United States3 FargoNorth Dakota, United States3 Winston-SalemNorth Carolina, United States2 New OrleansLouisiana, United States2 MemphisTennessee, United States2 AlbuquerqueNew Mexico, United States2 WichitaKansas, United States2 HonoluluHawaii, United States2 SpartanburgSouth Carolina, United States2 Sioux FallsSouth Dakota, United States2 BoiseIdaho, United States2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02728596 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.